Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Rothberg

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
The Yale Journal of Biology and Medicine|November 30, 2012
Bioinformatics. IntroductionJonathan Rothberg, Barry Merriman, Gadareth Higgs
Autophagy|March 29, 2017
B-cell non-Hodgkin lymphoma: Selective vulnerability to PIKFYVE inhibitionSophia Gayle, Sean Landrette, Neil Beeharry, et al.
Blood|January 21, 2017
Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphomaSophia Gayle, Sean Landrette, Neil Beeharry, et al.
Blood Advances|November 22, 2019
LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AMLNeil Beeharry, Sean Landrette, Sophia Gayle, et al.
JAMA Neurology|September 8, 2020
Assessment of Brain Injury Using Portable, Low-Field Magnetic Resonance Imaging at the Bedside of Critically Ill PatientsKevin N Sheth, Mercy H Mazurek, Matthew M Yuen, et al.
Nature Communications|August 26, 2021
Portable, bedside, low-field magnetic resonance imaging for evaluation of intracerebral hemorrhageMercy H Mazurek, Bradley A Cahn, Matthew M Yuen, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
The Yale Journal of Biology and Medicine|November 30, 2012
Bioinformatics. IntroductionJonathan Rothberg, Barry Merriman, Gadareth Higgs
Autophagy|March 29, 2017
B-cell non-Hodgkin lymphoma: Selective vulnerability to PIKFYVE inhibitionSophia Gayle, Sean Landrette, Neil Beeharry, et al.
Blood|January 21, 2017
Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphomaSophia Gayle, Sean Landrette, Neil Beeharry, et al.
Blood Advances|November 22, 2019
LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AMLNeil Beeharry, Sean Landrette, Sophia Gayle, et al.
JAMA Neurology|September 8, 2020
Assessment of Brain Injury Using Portable, Low-Field Magnetic Resonance Imaging at the Bedside of Critically Ill PatientsKevin N Sheth, Mercy H Mazurek, Matthew M Yuen, et al.
Nature Communications|August 26, 2021
Portable, bedside, low-field magnetic resonance imaging for evaluation of intracerebral hemorrhageMercy H Mazurek, Bradley A Cahn, Matthew M Yuen, et al.
Pageof 1